Edition:
United Kingdom

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

136.80USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$136.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
134,130
52-wk High
$137.10
52-wk Low
$31.70

Latest Key Developments (Source: Significant Developments)

Foundation Medicine, Pfizer Announce Partnership To Develop Companion Diagnostics For Pfizer’S Oncology Portfolio
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE AND PFIZER ANNOUNCE BROAD PARTNERSHIP TO DEVELOP COMPANION DIAGNOSTICS FOR PFIZER’S ONCOLOGY PORTFOLIO.FOUNDATION MEDICINE - PARTNERSHIP FOCUSES ON DEVELOPMENT, REGULATORY SUPPORT AND COMMERCIALIZATION OF COMPANION DIAGNOSTICS.FOUNDATION MEDICINE - CENTERS FOR MEDICARE & MEDICAID SERVICES ISSUED PRELIMINARY NATIONAL COVERAGE DETERMINATION FOR FOUNDATIONONE CDX.FOUNDATION MEDICINE INC - FINAL POLICY FOR FOUNDATIONONE CDX IS EXPECTED TO ISSUE DURING Q1 OF 2018.  Full Article

Foundation Medicine Reports Preliminary 2017 Results
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Foundation Medicine Inc ::FOUNDATION MEDICINE REPORTS PRELIMINARY 2017 RESULTS.- ‍ PRELIMINARY 2017 TOTAL REVENUE OF APPROXIMATELY $152.9 MILLION, A 31% YEAR OVER YEAR INCREASE​.- ‍ PRELIMINARY UNAUDITED TOTAL REVENUE OF APPROXIMATELY $48.9 MILLION FOR Q4 OF 2017​.Q4 REVENUE VIEW $39.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $142.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Foundation Medicine Q3 loss per share $0.90
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Foundation Medicine Inc :Foundation Medicine announces 2017 third quarter results and recent highlights.Q3 loss per share $0.90.Sees FY 2017 revenue $135 million to $145 million.Q3 revenue $42.7 million versus I/B/E/S view $38 million.Q3 earnings per share view $-1.10 -- Thomson Reuters I/B/E/S.  Full Article

Foundation Medicine Inc - FoundationOne accepted by FDA and CMS for Parallel Review and FDA Expedited Access Pathway
Tuesday, 2 Aug 2016 

Foundation Medicine Inc : FoundationOne® accepted by FDA and CMS for parallel review and FDA expedited access pathway . FDA also accepted foundation medicine's request for review as part of its Expedited Access Pathway (EAP) for breakthrough devices .Foundation Medicine Inc says based on discussions with FDA and CMS, Foundation Medicine believes parallel review will conclude in second half of 2017.  Full Article

Deals of the day-Mergers and acquisitions

June 19 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: